Lactate is a key myocardial energy source. Lactate metabolism is altered in a variety of conditions, such as exercise and diabetes mellitus. However, to our knowledge, noninvasive quantitative measurements of myocardial lactate metabolism have never been performed because of the lack of an adequate radiotracer. In this study we tested L-3-11 C-lactate ( 11 C-lactate) as such a tracer. Methods: Twenty-three dogs were studied under a wide range of metabolic interventions. 11 C-Lactate and 13 C-lactate were injected as boluses and PET data were acquired for 1 h. Concomitant arterial and coronary sinus (ART/CS) blood samples were collected to identify 13 C-lactate metabolites and to measure fractional myocardial extraction/production of 11 C metabolite fractions ( 11 C acidic: 11 CO 2 and 11 C-lactate; 11 C basic: 11 C-labeled amino acids; and 11 C neutral: 11 C-glucose). Lactate metabolism was quantified using 2 PET approaches: monoexponential clearance analysis (oxidation only) and kinetic modeling of PET 11 C-myocardial curves. Results: Arterial 11 C acidic, neutral, and basic metabolites were identified as primarily 11 C-labeled lactate 1 pyruvate, glucose, and alanine, respectively. Despite a significant contribution of 11 C-glucose (23%-45%) and 11 C-alanine (,11%) to total arterial 11 C activity, both were minimally extracted (1)/produced(2) by the heart (1.7% 6 1.0% and 20.12% 6 0.84%, respectively). Whereas extraction of 11 C-lactate correlated nonlinearly with that of unlabeled lactate extraction (r 5 0.86, P , 0.0001), 11 CO 2 production correlated linearly with extraction of unlabeled lactate (r 5 0.89, P , 0.0001, slope 5 1.20 6 0.13). In studies with physiologic free fatty acids (FFA) (415 6 216 nmol/mL), 11 C-lactate was highly extracted (32% 6 12%) and oxidized (26% 6 14%), and PET monoexponential clearance and kinetic modeling analyses resulted in accurate estimates of lactate oxidation and metabolism. In contrast, supraphysiologic levels of plasma FFA (4,111 6 1,709 nmol/mL) led to poor PET estimates of lactate metabolism due to negligible lactate oxidation (1% 6 2%) and complete backdiffusion of unmetabolized 11 C-lactate into the vasculature (28% 6 22%). Conclusion: Under conditions of net lactate extraction, L-3-11 Clactate faithfully traces myocardial metabolism of exogenous lactate. Furthermore, in physiologic substrate environments, noninvasive measurements of lactate metabolism are feasible with PET using myocardial clearance analysis (oxidation) or compartmental modeling. Thus, L-3-11 C-lactate should prove quite useful in widening our understanding of the role that lactate oxidation plays in the heart and other tissues and organs.
Derangement s in myocardial carbohydrate metabolism have been associated with impairment in cardiac function in diverse conditions ranging from normal aging (1, 2) to diabetes mellitus (3, 4) , ischemic heart disease (5), and heart failure (6) . Because of its inherent quantitative capabilities and diversity of metabolic radiotracers, PET has played a key role in characterizing perturbations in myocardial carbohydrate use associated with all of these conditions (7) (8) (9) (10) (11) . To date, however, measurements of myocardial carbohydrate metabolism in humans have focused solely on glucose use because of the availability of excellent PET tracers of glucose uptake and metabolism such as 18 F-FDG (8,10) and 1-11 Cglucose (7, 9, 11) .
As a key substrate for myocardial carbohydrate oxidation, lactate uptake and oxidation increases under a variety of conditions, including increases in cardiac work and plasma lactate levels (12) . Moreover, alterations in lactate metabolism appear to play an important role in diabetic heart disease (13) . Currently, measurements of myocardial lactate metabolism in humans are limited to invasive methods that require arterial (ART) and coronary sinus (CS) sampling due to the lack of a suitable PET lactate tracer.
In past years, the radiochemistry group in our institution was successful in labeling L-lactate in the third carbon (L-3-11 C-lactate) (14) . For the purposes of modeling, the labeling of L-lactate on the C-3 position (L-3-11 C-lactate) is advantageous. For example, if lactate is labeled in the C-1 position, 11 CO 2 will be released when pyruvate is converted to acetyl-CoA by pyruvate dehydrogenase. If lactate is labeled in the C-3 position, however, the labeled carbon is transferred to acetyl-CoA and is not released as 11 CO 2 until after its entry and cycling in the tricarboxylic acid (TCA) cycle. Consequently, the slower turnover time for L-3-11 C-lactate in myocardium will potentially enhance our ability to measure the myocardial kinetics of the tracer. Accordingly, the purposes of the current study were (a) to determine how faithfully L-3-11 C-lactate traces myocardial lactate uptake and oxidation in vivo based on arterial and coronary sinus sampling and (b) to develop a compartmental model that would allow for noninvasive measurements of myocardial lactate use and oxidation by PET and L-3-11 C-lactate.
MATERIALS AND METHODS

Animal Preparation
All animal experiments were conducted in compliance with the Guidelines for the Care and Use of Research Animals established by Washington University's Animal Studies Committee. The purpose-bred 20-to 25-kg mongrel dogs were fasted, anesthetized, and instrumented as reported previously (15, 16) . Catheters were placed in the thoracic aorta via the femoral arteries for monitoring of arterial blood pressure and arterial sampling. One femoral vein was cannulated to obtain venous blood samples and to administer drugs. A coronary sinus catheter was placed via the right external jugular vein under fluoroscopic guidance as previously described (15, 16) .
To achieve a wide range in myocardial lactate uptake and oxidation, 23 dogs were studied under various interventions initiated 60-90 min before imaging (15, 16) . To enhance lactate uptake and oxidation, 5 dogs were studied during lactate infusion. Sodium L-(1)-lactate diluted in phosphate buffer (0.06 M NaH 2 PO 4 and 0.0134 M Na 2 HPO 4 ) was infused at a rate of 130 mmol/kg/min to increase plasma lactate concentration approximately 3-3.5 times over normal fasting levels (LACTATE). Further enhancement of lactate uptake and oxidation was achieved by concomitant administration of lactate and phenylephrine (0.84-1.6 mg/kg/min) in 7 dogs (LAC/PHEN). To increase lactate extraction and oxidation, 4 other dogs were studied during a hyperinsulinemic-euglycemic clamp, which entailed a continuous infusion of insulin (70 mU/kg/h) with an adjustable infusion of 20% dextrose (CLAMP). Finally, inhibition of lactate oxidation was attained in 7 dogs by infusion (1 mL/min) of 20% Intralipid ([IL] Fresenius Kabi Clayton, LP).
Imaging and ART/CS Sampling Protocol
All PET studies were performed on a Siemens ECAT 962 HR1. The electrocardiogram, arterial blood pressure, and heart rate were monitored throughout the study. A transmission scan was performed to correct for photon attenuation. To measure myocardial blood flow (MBF), 15 O-water (14.8 MBq/kg) was administered as an intravenous bolus and dynamic PET data were acquired for 5 min (5-s frames). After allowing for decay of 15 O radioactivity, 185-962 MBq of L-3-11 C-lactate ( 11 C-lactate) was administered as a bolus, followed by 60 min of dynamic data collection. To identify the 11 C-metabolites present in ART and CS blood samples, 50 mmol/kg of L-3-13 C-bolus (sodium salt; Cambridge Isotope Laboratories, Inc.) were injected into 8 dogs (2 IL, 1 CLAMP, 2 LACTATE, and 3 LAC/PHEN) immediately after the 11 C-lactate bolus injection. Simultaneous ART and CS blood samples were obtained at 5, 10, 15, 20, 25, 30, 45 , and 60 min after 11 C-and 13 C-lactate administration for the measurement of 11 C-lactate, 11 CO 2 (an indicator of lactate oxidation), 11 C-neutral, and 11 C-basic metabolites (17) , as well as for measurements of ART 13 C-labeled lactate, pyruvate, glucose, and alanine. Paired ART/CS blood samples were also collected to determine blood gases, plasma substrates (glucose, free fatty acids [FFA] , lactate), and insulin at baseline, before 11 C, and 30 and 60 min of imaging.
Radiochemical Synthesis
All the reagents were obtained from Sigma-Aldrich and used without further purification. The tracer L-3-11 C-lactate was synthesized using a modification of a 2-step enzymatic synthesis previously described (18) . Briefly, a conical vial containing 3 mg of N-(diphenylmethylene) glycine t-butyl ester dissolved in 180 mL of acetonitrile/N,N-dimethylformamide and 4 mL of 5N KOH was used to trap the 11 C-methyl iodide (GE PETrace MeI Microlab). After 5 min of heating at 87°C, the reaction mixture was diluted with ethanol/acetonitrile and transferred to a conical flask containing 600 mL of 6N HCl, where it was hydrolyzed and taken to dryness at 150°C-170°C. The cooled contents were redissolved with 0.1 M Tris buffer, pH 8.5, and the enzymes and cofactors were premixed and added: a-ketoglutarate, pyridoxal-5-phosphate, flavin adenine dinucleotide, catalase, glutamic pyruvic transaminase, D-amino acid oxidase, and L-lactic dehydrogenase with b-nicotinamide adenine dinucleotide (reduced form). The mixture was incubated for 6-8 min at 50°C. The enzymes were heat-denatured and removed by passing the mixture through a cation-exchange resin cartridge, and the desired product was eluted with water. After adjusting the pH to 6-7 and filtering through a 0.22-mm filter, we obtained a sterile and pyrogen-free, clear, colorless solution ready for injection. The total radiochemical yield at end of synthesis (EOS) was 30%-45%. We consistently obtained from 555-1,480 MBq of product with a radiochemical purity of .95%, in a total synthesis time of 50 min that included the 12-min preparation of 11 C-methyl iodide. The product was found to be enzyme-free and contained ,5 ppm total of nonradioactive lactic acid, in a 5-mL injectate. The enantiomeric purity was determined on a Chirex D-penicillamine specialty column (Phenomenex) and found it to be .98% as L-3-11 C-lactate.
Measurements of Unlabeled Plasma Substrates
Plasma glucose and lactate levels were assayed enzymatically with a 2300 STAT Plus Analyzer (YSI Life Sciences). Plasma FFA levels were measured using an enzymatic colorimetric method (NEFA C kit; Wako Chemicals USA). Plasma insulin was measured by radioimmunoassay (Linco Research Co.).
Measurements of Plasma 11 C-Lactate and its Metabolites
Plasma 11 C-lactate was separated from its metabolites by using a solid-phase approach (17) . An anion-exchange resin (AG1-X4, 100-200 mesh, formate form; Bio-Rad) trapped the acidic metabolites ( 11 C-lactate and 11 CO 2 as NaH 11 CO 3 ). A cation-exchange resin (AG50W-X8, 200-400 mesh; Bio-Rad) trapped the basic metabolites with the neutral metabolites found in the final eluate. The 11 CO 2 fraction in plasma was determined separately as previously described (17) and subtracted from total counts found on the acidic resin to obtain 11 C-lactate in plasma. With this approach, 11 C-lactate measurement probably also included some 11 C-pyruvate. On the other hand, the basic metabolites retained in the cation resin might include, besides alanine, other amino acids such as glutamate and glutamine, whereas the neutral fraction might include, besides glucose, some glycerol.
Measurement of Plasma 13 C-Lactate and Its Metabolites
Plasma 13 C-labeled lactate, pyruvate, and alanine enrichments were determined by gas chromatography mass spectrometry ([GC/ MS] 5973 MSD; Agilent Technologies) in a single run using tertbutyldimethylsilyl (TBDMS) or silylquinoxalinol TBDMS (for pyruvate) derivatives, monitoring ions at m/z 260 and 261 (for both lactate and alanine) or m/z 217 and 218 (for pyruvate). 13 CGlucose enrichment was determined in a separate GC/MS run using the isopropylidine derivative, monitoring ions at m/z 287, 288, and 289 (to account for any doubly labeled glucose). Internal standards uniformly labeled with 13 C (e.g., U-13 C-lactate) were used to quantify the concentration of unlabeled substrate (e.g., lactate), which was then multiplied by the enrichment to derive the concentration of labeled substrate (e.g., 3-13 C-lactate).
PET Image Analysis and Measurement of MBF
Myocardial 15 O-water and 11 C-lactate images were reoriented to generate standard short-axis and long-axis views, and composite PET images of myocardial 15 O-water and 11 C-lactate were obtained. Blood and myocardial time-activity curves were then generated as previously described (15, 16) . MBF (mL/g/min) was quantified from blood and myocardial time-activity curve generated from myocardial PET images of 15 O-water using a compartmental modeling approach developed and validated previously by our group (15, 16) .
PET Measurements of Exogenous Lactate Metabolism
To assess whether oxidation of exogenous myocardial lactate could be measured noninvasively from PET myocardial clearance of 11 C-lactate, a monoexponential equation was fitted to the late clearance (starting at 20 min after tracer injection) of PET myocardial time-activity curves, and the estimated rate constants (k mono , min 21 ) were compared with 11 CO 2 production measured from ART/CS blood samples using linear regression analysis. The estimated regression line was then used to convert k mono values to fractional lactate oxidation. To further investigate whether exogenous lactate extraction, backdiffusion, and oxidation could be assessed with PET and 11 C-lactate, a 2-compartment kinetic model was implemented (Fig. 1) . The model was based on direct ART/ CS plasma measurements of 11 C-lactate and its metabolites in myocardium, which showed that once it is taken up by myocardium, 11 C-lactate is either oxidized or returned back to the vasculature (backdiffusion), with negligible conversion into 11 Cpyruvate and 11 C-alanine. Thus, the model configuration is based on the assumption that no tracer is retained by the myocardium (19) .
The differential equations describing the modeling approach ( Fig. 1 ) and the calculations of key rates of lactate metabolism are described below. The transport of tracer from one compartment to another can be described by the following differential equations:
Eq. 2 where C la (t) is 11 C-lactate blood concentration (counts/mL) over time (input function), and q n is the concentration of tracer in compartment n (counts/g). K 1 (mL/g/min) represents 11 C-lactate uptake into and washout from the vascular compartment, and k 2 (min 21 ) represents the transfer of tracer from the vascular to the extravascular/cytosolic compartment, where 11 C-lactate is either back-diffused at a rate of k 3 (min 21 ) or converted to pyruvate, transported into the mitochondrion, and oxidized at a rate of k 4 (min 21 ).
Total tracer concentration in myocardium as a function of time was defined as the sum of tracer concentration in each compartment:
Eq. 3
Correction for partial-volume and spillover effects were accounted for within the model equation as previously described (15, 16) . Once model parameters were estimated using wellestablished numeric methods (20, 21) , q i (t) quantities were calculated as functions of rate constants by assuming the physiologic system is in steady state conditions-that is, differential equations are set to zero:
Eq. 4
The following metabolic fluxes were then calculated from Equations 4 and 5.
Lactate uptake ðmL=g=minÞ 5 k 2 Á q 1 : Eq. 6
Lactate backdiffusion ðmL=g=minÞ 5 k 3 Á q 2 : Eq. 7
Lactate oxidation ðmL=g=minÞ 5 ðLactate uptake 2 Lactate backdiffusionÞ 5 k 4 Á q 2 :
Eq. 8
Myocardial fractional quantities were calculated from metabolic fluxes by dividing a given flux by MBF (mL/g/min). Measurements of the myocardial fate of lactate (use, backdiffusion, and oxidation, nmol/g/min) can be calculated as the product of plasma lactate concentration (nmol/mL) and the corresponding flux (mL/g/min).
Statistical Analysis
All data are presented as mean 6 SD. Comparisons between 11 C-and 13 C-metabolites were done by paired t test. Differences among interventions were compared by means of 1-way ANOVA, where the post hoc Fisher test was used to localize differences among groups. Correlations were calculated by linear regression analyses. A P value , 0.05 was considered statistically significant.
RESULTS
MBF and Oxygen Consumption
The heart rate ( By design, insulin levels were the highest in CLAMP (P , 0.05 vs. all groups), resulting in the highest myocardial glucose extraction and use in CLAMP (P , 0.05 vs. all groups). Plasma FFA levels were the highest in IL, resulting in the highest FFA use (P , 0.05 vs. all groups) ( Table 1) . Lactate infusion increased plasma lactate concentrations 4-fold above those in IL and CLAMP (P , 0.05). Comparable levels of plasma lactate in IL and CLAMP resulted in very different levels of lactate extraction with negligible extraction in IL and the highest among all groups in CLAMP (P , 0.05 vs. CLAMP, LAC/PHEN). Lactate use was the lowest in IL and the highest in LAC/PHEN (P , 0.01). Despite no differences in plasma insulin or substrate levels between LACTATE and LAC/PHEN, a 60% increase in cardiac work in LAC/PHEN (as measured by RPP) resulted in more than a doubling of myocardial lactate use (nmol/g/min) (P , 0.05), reflecting the combined effects of increased MBF and extraction of lactate.
Characterization of 11 C Acidic, Neutral, and Basic Metabolites Figure 2 shows the time course of arterial 11 C acidic (A), neutral (B), and basic (C) metabolites and arterial 13 Clactate 1 pyruvate (A), glucose (B), and alanine (C). As expected, 13 C-lactate metabolites ( 13 C-glucose and -alanine) appeared in arterial blood as lactate was removed from blood. The same pattern was observed for the 11 C neutral, basic, and acidic fractions. This close match between the time course of plasma 11 C and 13 C metabolites for lactate 1 pyruvate, glucose, and alanine strongly suggests the 11 Clactate 1 pyruvate, 11 C-glucose, and 11 C-alanine are the primary labeled metabolites. However, a 45% 6 20% mean difference between the overall fractional contribution of 13 C-alanine and 11 C-basic fraction (0.12 6 0.04 and 0.18 6 0.05, respectively, P , 0.0001) is indicative of the presence of other basic metabolites such as glutamate and glutamine. In contrast, the contributions of 13 C-glucose and 11 C-neutral fraction to total arterial activity were no different (0.25 6 13 and 0.26 6 0.10, respectively, P 5 not significant). 13 C-Pyruvate isotopic enrichment was the same as that of 13 C-lactate 5-min after tracer injection, demonstrating that conversion of lactate to pyruvate occurred quite rapidly. Overall, 8% of the acidic fraction could be attributed to pyruvate, ranging from 5% in the CLAMP to 12% in LACTATE. Accumulation of 11 C-lactate, 11 CO 2 , 11 C-neutral, and 11 C-basic metabolites over time in arterial blood for each intervention is shown in supplemental Figure S1 (supplemental Figures S1 and S2 are available online only at http:// jnm.snmjournals.org). 11 C-Lactate decreased in all interventions over time, whereas 11 CO 2 and 11 C-neutral metabolites increased and 11 C-basic metabolites remained unchanged. As expected, 11 C-lactate contribution was the highest in LACTATE and LAC/PHEN and the lowest in IL. The highest 11 CO 2 contribution occurred in CLAMP. Thirty minutes after tracer injection, the contribution of 11 Cneutral metabolites to total 11 C arterial activity was greater than that of 11 C-lactate in IL, resulting in the highest contribution of 11 C-neutral metabolites to total arterial 11 C activity among all interventions. By 60 min, the contribution of 11 C-neutral metabolites to total arterial 11 C activity ranged from 23% to 28% in CLAMP, LACTATE, and LAC/ PHEN to 45% in IL and was greater than the contribution of 11 C-basic metabolites, which overall contributed ,11%. 11 CO 2 contribution averaged 10%-13% in IL, LACTATE, and LAC/PHEN and 27% in CLAMP.
Myocardial extraction/production fractions obtained from ART and CS blood samples are shown in supplemental Figure S2 . 11 C-Lactate extraction was not different from that of lactate in CLAMP and LACTATE and was significantly higher in LAC/PHEN at 60 min after tracer injection (P , 0.05). In contrast, during IL, 11 C-lactate plasma levels were higher in CS than in ART, resulting in an apparent net 11 C-lactate production ranging from 0.60 6 0.14 at 5 min to 0.28 6 0.22 at 60 min.
Thirty minutes after tracer injection, 11 CO 2 production did not differ from lactate extraction in all non-Intralipid interventions, but was significantly lower than 11 C-lactate extraction at 60 min in LAC/PHEN (P , 0.005). During CLAMP, LACTATE, and LAC/PHEN, 11 C-neutral metabolites and 11 C-basic metabolites extractions were relatively low compared with lactate and 11 C-lactate extraction. In contrast, during IL, by 5 min after injection 11 C-neutral metabolites extraction was as high as lactate extraction and declined over time, whereas 11 C-basic metabolites were minimally produced during the entire study. In theory, the apparent net production of 11 C-lactate observed in IL could be attributed to either production of 11 C-lactate from 11 Cglucose or exogenous 11 C-lactate entering the myocyte and leaving it unchanged (backdiffusion). However, because the contribution of 11 C-glucose ( 11 C-neutral metabolites) to myocardial 11 C activity in IL was minimal (ranging from 0.046 6 0.045 at 5 min to 0.01 6 0.02 at 60 min), the apparent production of 11 C-lactate activity can be attributed only to 11 C-lactate backdiffusion. 11 C activity (open symbols) for 11 C-lactate (A), 11 C-neutral (B), and 11 Cbasic (C) metabolites and (solid symbols) for arterial 13 C-lactate 1 13 C-pyruvate (A), 13 C-glucose (B), and 13 C-alanine (C). 11 C data represent fractions of total 11 C arterial activity, and 13 C data represent fractions of 13 C-(lactate 1 pyruvate 1 glucose 1 alanine). Graphs represent mean values for 8 dogs studied with 13 C-lactate 6 SD. *P , 0.05 vs. 13 Clactate 1 13 C-pyruvate; $ P , 0.0001 vs. 13 C-alanine.
A significant nonlinear correlation was observed between labeled and unlabeled lactate extractions (Fig. 3A) , with apparent 11 C-lactate production in IL. It is apparent that the key contributor to the nonlinearity of the regression is the decline in extraction of 11 C-lactate in CLAMP as unlabeled lactate extraction increases, which could be attributed to the higher concentration of 11 C-lactate than unlabeled lactate in CS due to 11 C-lactate production from extracted 11 C-glucose ( 11 C-neutral metabolites in supplemental Fig. S2, CLAMP) . In contrast, there was a strong linear correlation between 11 CO 2 production and extraction of unlabeled lactate (Fig. 3B) with a slope not different from 1 (r 5 0.89, P , 0.0001, slope 5 1.20 6 0.13). Because of the apparent production of 11 C-lactate in the IL group, a nonlinear correlation was observed between 11 CO 2 production and 11 C-lactate extraction (r 5 0.80, P , 0.0001). Removing the IL data resulted in significant linear correlation between 11 CO 2 production and either unlabeled extraction (r 5 0.82, P , 0.0001, slope 5 1.14 6 0.20) or 11 C-lactate extraction (r 5 0.58 P , 0.05, slope 5 0.68 6 0.26), with a significantly higher slope observed with unlabeled extraction than 11 C-lactate extraction (P ,0.05).
PET Measurements of 11 C-Lactate Metabolism
Representative myocardial PET images of L-3-11 C-lactate early uptake (5-10 min after tracer injection) and the corresponding 11 C-time-activity curves are shown in Figure 4 .
Tracer uptake was observed in all interventions with high lactate uptake (CLAMP: 0.38, LACTATE: 0.32, and LAC/PHEN: 0.28 mL/g/min) as well as in IL, where net lactate uptake was minimal (0.04 mL/g/min), corroborating the observations obtained from ART/CS blood samples, where severe suppression of myocardial 11 C-lactate oxidation in IL resulted in initial uptake before backdiffusion of unused tracer (supplemental Fig. S2 ). The early clearance of myocardial 11 C activity (Fig. 4A, solid dots, 1-20 min) with no apparent retention of tracer observed in the IL study is consistent with significant backdiffusion of tracer and negligible net lactate extraction and oxidation measured from the direct ART/CS measurements (supplemental Fig. S2 ). In the rest of the interventions (Figs. 4B-4D ), myocardial timeactivity curves displayed a plateau before clearance of tracer (5-10 min), indicative of significant tracer retention before it is removed from myocardium as 11 C-lactate (backdiffusion) or as 11 CO 2 .
Lactate oxidation estimated from PET clearance analysis correlated well with 11 CO 2 production (r 5 0.80, P , 0.0001), with the slope and intercept not different from 1 and 0, respectively. However, estimates of lactate oxidation were quite variable, especially in the IL study, where estimates ranged from 20.13 to 0.18 for a range in 11 CO 2 production values between 20.003 and 0.039. After removing the IL study (Fig. 5A) , a significant but weaker correlation was obtained (r 5 0.73, P , 0.001), with the slope not different from 1 and the intercept not different from 0.
Excellent fits to the 4-rate-constant 2-compartment kinetic model were observed in all non-IL studies, resulting in good estimates of lactate oxidation (Fig. 5B ) (r 5 0.81, P , 0.0005). In IL, PET kinetics did not fit the model because severe inhibition of lactate oxidation resulted in almost complete backdiffusion of myocardial 11 C-lactate. This observation was corroborated by fitting PET kinetics to a simple 2-rate-constant, 1-compartment model describing exclusively uptake and washout of tracer. Excellent fits were obtained for all 7 IL studies.
Components of lactate metabolism estimated from kinetic modeling for nonintralipid studies are shown in Figure 5C . Initial tracer extraction and backdiffusion were the highest in LACTATE and CLAMP and the lowest in LAC/PHEN. Contribution of lactate oxidation to overall myocardial oxygen consumption (lactate oxidation/MVO 2 ) was the lowest in CLAMP where substrate competition was present, with no differences in lactate oxidation/MVO 2 between the LACTATE and LAC/PHEN.
DISCUSSION
To our knowledge, we have demonstrated for the first time that 11 C-lactate labeled in the third carbon follows the myocardial fate of exogenous lactate extraction, where it is either oxidized or backdiffused; with minimal myocardial FIGURE 3. Correlation between 11 C-lactate extraction/ production (y-axis, A) or 11 CO 2 production (y-axis, B) and extraction fraction of unlabeled lactate (x-axis, A and B).
contribution of secondarily labeled 11 C-glucose and 11 Cbasic metabolites to myocardial 11 C activity. Furthermore, in interventions with physiologic FFA levels, myocardial PET clearance and kinetic modeling analyses resulted in good estimates of lactate oxidation (clearance analysis) and overall lactate metabolism, including initial uptake, backdiffusion and oxidation (kinetic model). In the presence of supraphysiologic levels of plasma FFA, both approaches failed due to severe inhibition of lactate oxidation resulting in very high levels of tracer backdiffusion.
Metabolism of L-3-11 C-Lactate: Direct Measurements
Arterial radiolabeled non-CO 2 acidic, neutral, and basic fractions obtained from 11 C-lactate represented lactate 1 pyruvate, glucose, and mostly alanine, respectively (Fig. 2) . Eight percent of the acidic fraction could be attributed to pyruvate. Reported percentages measured in healthy individuals after an overnight fast averaged 16% (22) . The most abundant 11 C fraction in arterial blood was lactate 1 pyruvate (43%), followed by neutral metabolites (glucose, 31%) and CO 2 (15%), with basic metabolites (primarily FIGURE 4. Representative PET timeactivity curves of L-3-11 C-lactate obtained from IL, CLAMP, LACTATE, or LAC/PHEN studies and corresponding myocardial images obtained 5-10 min after tracer injection and depicting primarily early tracer uptake. Images are displayed on horizontal long axis. Blood 11 C 5 11 C time-activity curves obtained from region of interest (ROI) placed on left atrium; blood 11 C-lactate 5 blood 11 C time-activity curves after removing 11 CO 2 , 11 C-neutral, and 11 C-basic metabolites; myocardial 11 C 5 11 C timeactivity curves obtained from ROI placed on lateral wall. A 5 apical wall; S 5 septal wall; L 5 lateral wall; LV 5 left ventricle.
FIGURE 5.
Correlation between PET measurements of fractional lactate oxidation and 11 CO 2 production for all non-IL studies obtained from monoexponential clearance analysis of the late myocardial 11 C-lactate kinetics (20-60 min) (A) and from kinetic modeling (B). Initial lactate extraction, backdiffusion, and oxidation normalized by MVO 2 for non-IL studies estimated from compartmental modeling of 11 C-lactate PET kinetic (C). Bar graphs represent intervention mean 6 SD. *P 5 0.08 vs. extraction or backdiffusion in LACTATE; y P 5 0.08 vs. oxidation/MVO 2 in CLAMP.
alanine) contributing 10% to total arterial 11 C activity (supplemental Fig. S1 ). The highest levels of arterial 11 Cglucose were observed in the IL study (45% of total 11 C activity vs. 26% in the non-IL interventions). The strong presence of 11 C-glucose in arterial blood is indicative of persistent gluconeogenesis from 11 C-lactate and consistent with enhanced gluconeogenesis in metabolic states with elevated plasma FFA levels, such as starvation and diabetes (23) .
Despite the relatively high 11 C-glucose concentrations and the significant presence of 11 C-basic metabolites in plasma, 11 C-glucose was minimally extracted by the heart, with no significant extraction of 11 C-basic metabolites (supplemental Fig. S2 ), suggesting that, under the conditions studied, secondarily labeled 11 C-lactate metabolites undergo minimal myocardial extraction and, therefore, should not interfere with noninvasive myocardial PET measurements of exogenous 11 C-lactate metabolism. These observations contrast with our recent study on measurements of glucose metabolism using 1-11 C-glucose, where myocardial contribution of secondarily labeled 11 C-lactate produced from 1-11 C-glucose was significant and had to be considered to accurately measure myocardial glucose metabolism beyond its initial uptake (24) .
Myocardial 11 C-lactate extraction was higher than that of unlabeled lactate in all non-IL interventions, resulting in 11 CO 2 production greater than lactate extraction (Fig. 3B) . These results are consistent with results of earlier studies in humans using arteriovenous measurements of 1-14 C-lactate and L-U-13 C-lactate (19, 25) . Greater myocardial extraction of tracer than unlabeled lactate was observed in these studies because of the simultaneous release of unlabeled lactate produced from glycolysis of unlabeled glucose. In a subsequent study (12) it was observed that the underestimation of true lactate extraction by measuring net lactate extraction also resulted in levels of exogenous lactate oxidation that, even though correlated well with net lactate extraction, were significantly higher than net lactate extraction.
In the presence of supraphysiologic plasma FFA levels and low lactate extraction, apparent production of 11 Clactate could not be attributed to production of 11 C-lactate from glycolysis of secondarily labeled 11 C-glucose, as minimal myocardial extraction of 11 C-glucose was observed in all interventions (supplemental Fig. S2 ). However, the positive correlation between plasma FFA levels and 11 C-lactate production observed in IL (r 5 0.75, P , 0.05) strongly suggests that this apparent production of lactate represents unoxidized myocardial 11 C-lactate that diffuses back into the vasculature due to severe inhibition of 11 C-lactate oxidation in the presence of high levels of acetyl-CoA derived from FFA oxidation (26, 27) . These observations clearly demonstrate that the primary fate of myocardial 11 C-lactate originating from exogenous 11 Clactate is either oxidation or backdiffusion. These assumptions are consistent with earlier observations in humans where oxidation of exogenous lactate accounted for practically all extracted 1-14 C-lactate (99.5%) as measured by NaH 14 CO 3 production in which all 14 Cs contributing to 14 CO 2 were trapped (19) .
In the present study, changes in 11 C-lactate oxidation among interventions as measured by 11 CO 2 production were consistent with expected changes in lactate oxidation due to insulin, substrate, and cardiac work changes. For instance, severe inhibition of 11 C-lactate oxidation was observed in the IL study, where supraphysiologic plasma FFA levels resulted in negligible lactate oxidation (supplemental Fig. S1, 60 min) . On the other hand, the highest levels of lactate oxidation were observed in CLAMP (supplemental Fig. S2, 60 min) , where low plasma levels of FFA due to inhibition of lipolysis by insulin, and the subsequent low FFA uptake and oxidation, resulted in enhanced lactate oxidation. These observations are in keeping with what is known about the regulation of pyruvate oxidation in the heart. Pyruvate oxidation is primarily regulated by FFA at the level of acetyl-CoA, where high levels of acetyl-CoA generated from FFA oxidation result in inhibition of carbohydrate oxidation by the pyruvate dehydrogenase complex (PDH). Conversely, low levels of acetyl-CoA from FFA oxidation activate the PDH complex, resulting in enhancement of glucose and lactate oxidation (26) (27) (28) (29) (30) (31) .
In the 2 interventions with supralactate plasma levels, increase in cardiac work, as demonstrated by the doubling of the RPP, resulted in a 2-fold increased in lactate oxidation. These observations are consistent with the well-known role of lactate during cardiac work, where it becomes a key myocardial respiratory substrate by increasing oxidation proportionally to cardiac work (6, 32, 33) . Thus, it appears evident that 11 C labeling of L-lactate in the third carbon position (L-3-11 C-lactate) results in an excellent tracer of myocardial lactate metabolism.
Metabolism of L-3-11 C-Lactate: PET Measurements
Currently, noninvasive measurements of myocardial lactate metabolism are not possible because of the lack of tracers or methodologies to be used in conjunction with difference images modalities such as magnetic resonance spectroscopy and PET. To evaluate whether noninvasive measurements of exogenous lactate metabolism could be attained using PET, 2 different methodologies were used: monoexponential analysis of myocardial PET 11 C-clearance (oxidation only) and kinetic modeling (lactate metabolism).
The strong correlation observed between lactate oxidation obtained from PET measurements of myocardial 11 C clearance rates (k mono ) and 11 CO 2 production (Fig. 5A) clearly shows that good indices of lactate oxidation can be obtained noninvasively with 11 C-lactate and PET using a simple clearance approach. However, as mentioned previously, the accuracy of the method declines markedly under conditions of excessive backdiffusion of intact tracer, such as under conditions of very low lactate oxidation.
Although indices of lactate oxidation can be quite useful, the strength of PET lies in its capacity for noninvasive and quantitative measurements of physiologic processes. The PET kinetic model implemented was based on the understanding of the myocardial fate of exogenous 11 C-lactate obtained from ART/CS measurements in which tracer taken into myocardium is either oxidized or back-diffuses into the vasculature (Fig. 1) . These observations are consistent with measurements of lactate oxidation in humans (19) , where it accounted for practically all extracted 1-14 C-lactate (99.5%) as measured by NaH 14 CO 3 production, in which all 14 Cs contributing to 14 CO 2 were trapped.
In this first attempt to model exogenous lactate metabolism, it was assumed that there were no detectable differences between 11 CO 2 produced from carboxylation or decarboxylation. However, some of the underestimation in lactate oxidation observed in the LAC/PHEN study (Fig.  5B ) might suggest otherwise, as during high cardiac work, faster depletion of the TCA cycle would result in increasing anaplerosis and, consequently, an increased contribution of anaplerotic 11 CO 2 to total lactate oxidation. Not surprisingly, modeling resulted in better estimates of lactate oxidation where clearance of tracer in myocardium is defined by 3 distinct washout rates-vascular lactate, myocyte lactate, and lactate oxidation (Fig. 1) -whereas clearance analysis allowed only for 2 washout rates.
Significance of Lactate Oxidation Measurements Using L-3-11 C-Lactate
In spite of the well-known fact that the heart uses a wide range of substrates, including FFA, glucose, lactate, and, to a lesser extent, pyruvate and ketone bodies, the great majority of cardiac substrate metabolism studies traditionally have concentrated on glucose and FFA use. This is most probably due, as has been proposed by others (34) , to the misperception that lactate is a minor fuel when compared with glucose and FFA. On the contrary, results of studies in isolated perfuse hearts, intact animals, and humans have demonstrated that lactate oxidation is a major cardiac fuel, contributing significantly to carbohydrate oxidation during cardiac work and elevated plasma lactate levels (12) with diminished contribution in ischemia and diabetes (5, 13) . To date, the lack of noninvasive lactate radiotracers has hampered our understanding of the critical role that lactate oxidation plays in the metabolic homeostasis of the heart and, consequently, the development of potential metabolic therapies designed to restore cardiac function by normalizing cardiac substrate metabolism. Thus, access to a novel noninvasive tracer should prove quite useful in widening our understanding of the role that lactate oxidation plays in the heart and other tissues and organs.
CONCLUSION
Under conditions of net lactate extraction, L-3-11 C-lactate traces myocardial metabolism of exogenous lactate faithfully. Moreover, under physiologic conditions of net lactate extraction, it is feasible to measure myocardial lactate metabolism using L-3-11 C-lactate in conjunction with PET and kinetic modeling. Use of PET and L-3-11 C-lactate should allow for the noninvasive measurements of myocardial lactate metabolism, thus permitting a more complete assessment of myocardial carbohydrate metabolism in physiologic as well as clinical studies.
